The median overall survival (mOS) in metastatic triple-negative breast cancer (mTNBC) varies depending on the treatment and patient characteristics. A study found mOS of 11.6 months after first-line treatment, 6.5 months after second-line, and 6.5 months after third-line. Some studies suggest mOS of 9-17 months for relapsed and metastatic TNBC. Other studies have reported mOS ranging from 6.6 months to 12+ months, depending on the specific treatment regimen.